Prodrug Compounds Sustained Release via Labile Linkages
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems face challenges in providing sustained release of certain active agents, particularly those with narrow therapeutic windows, due to unreliable control over release rates and irregular release patterns, which complicates patient compliance and dosing frequency.
Innovation Solution
Development of prodrug compounds with labile aldehyde-linked moieties that reduce solubility and polarity, such as those derived from lactam, amide, imide, sulfonamide, carbamate, urea, benzamide, and acylaniline pharmacophores, which form insoluble depots upon administration, allowing for extended and controlled release of the parent drug.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If microencapsulation or enteric coating technologies are used to achieve sustained release, then stability and time-release properties are improved, but release rate control becomes unreliable and dosing precision deteriorates
Solution Approach 1:
The patent changes the chemical structure of the drug molecule itself by forming covalent bonds with carrier molecules (e.g., forming esters, amides, or other labile linkages), thereby modifying parameters such as solubility, stability, and release kinetics. This allows precise control over release rate through chemical design rather than relying on physical encapsulation matrices with variable diffusion properties.
Solution Approach 2:
The invention extracts the active pharmacophore from the parent drug molecule and temporarily masks it through covalent attachment to a carrier, creating a prodrug that releases the active agent through controlled chemical transformation. This separates the delivery function from the therapeutic function, allowing independent optimization of both.
2Ease of operation
If water-soluble microspheres are used for sustained release, then ease of administration is improved, but infinite swelling occurs causing burst release and reducing sustained release capability
Solution Approach 1:
The patent changes the solubility parameters of the drug by forming prodrugs with controlled hydrophobicity. By selecting carriers that create appropriately lipophilic prodrugs, the formulation achieves sustained release without the infinite swelling problem of water-soluble microspheres, while maintaining acceptable administrability.
3Object-affected harmful factors
If enteric coating dependent on pH is used for release control, then protection in stomach is improved, but release rate becomes difficult to control due to pH and residence time variations
Solution Approach 1:
The patent replaces the mechanical/physical pH-dependent release mechanism with a chemical mechanism based on controlled hydrolysis or enzymatic cleavage of labile linkages in the prodrug. This chemical approach provides more predictable and controllable release kinetics independent of gastrointestinal pH fluctuations and residence time variations.
4Ease of operation
If dosing frequency is reduced to improve patient compliance, then ease of operation is improved, but maintaining stable serum levels within therapeutic window becomes more difficult
Solution Approach 1:
The patent creates prodrugs designed to release the active drug continuously over extended periods (days to weeks) through controlled chemical transformation in the body. This continuous release mechanism maintains stable serum concentrations within the therapeutic window, enabling reduced dosing frequency while preserving reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug compounds achieve longer duration of action per dose, providing sustained therapeutic levels for hours, days, or months, enhancing patient compliance by reducing dosing frequency and maintaining stable serum concentrations within the therapeutic window.
Implementation Method 1
prodrugs of lactam, amide, imide, sulfonamide, carbamate, urea, benzamide, and acylaniline containing pharmacophores
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.